Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 7/2020

30.04.2020 | Original Article – Cancer Research

Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication

verfasst von: Ramy A. Abdelsalam, Ibrahim Khalifeh, Alan Box, Maria Kalantarian, Sunita Ghosh, Hatem Abou-Ouf, Tamara Lotfi, Mohammed Shahait, Nallasivam Palanisamy, Tarek A. Bismar

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

To investigate the incidence and prognostication of ERG, PTEN and SPINK1 protein expressions in prostate cancer cohort of Middle Eastern descent in comparison to published data from Western population.

Methods

Immunohistochemistry for ERG, PTEN and SPINK1 was performed in a cohort of localized PCA (n = 340). The data were correlated to pathological and clinical outcomes and compared to Western populations.

Results

ERG expression and PTEN loss were noted in 123/288 (42.7%) and 91/297 (30.6%) of patients, respectively. SPINK1 expression was assessed in a subset of cases, noted in 6/150 (4%) of patients. Only ERG expression was associated with grade groups, being more common in the lower grade groups (1–3 vs 4–5; p = 0.04). In contrast to the Western population, PTEN loss foci were more likely to be ERG negative, observed in 81% of tumor foci and patients with PTEN neg/ERG pos were more likely to exhibit biochemical recurrence (OR 2.831; 95% CI 1.10–726, p = 0.03). This association remained significant in multivariate analysis (OR 2.68; 95% CI 0.98–7.33, p = 0.05), after adjusting for GG, path stage and surgical margin.

Conclusion

This study documents significant differences in key molecular events in PCA in Middle Eastern population compared to Western populations that could explain differences in PCA incidence, progression and prognostication. ERG, PTEN and SPINK1 genomic alteration occur less frequently and the enrichment of ERG for PTEN loss is not observed. Additionally, patients with combined PTEN loss/ERG positive are at highest risk for BCR vs North American Caucasian population where PTEN loss alone seems to be associated with the worst clinical outcome. The data presented here further support differences in clonal evolution between Middle Eastern and Western population in relation to PCA and add further insight to understanding PCA molecular pathways.
Literatur
Zurück zum Zitat Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL (2016) A Prospective investigation of PTEN Loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djv346 CrossRefPubMed Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, Hicks JL, Wilson KM, Rider JR, Sesso HD, Fiorentino M, Flavin R, Finn S, Giovannucci EL, Loda M, Stampfer MJ, De Marzo AM, Mucci LA, Lotan TL (2016) A Prospective investigation of PTEN Loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst. https://​doi.​org/​10.​1093/​jnci/​djv346 CrossRefPubMed
Zurück zum Zitat Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3:72ra17. doi: 10.1126/scitranslmed.3001498CrossRef Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM (2011) Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med 3:72ra17. doi: 10.1126/scitranslmed.3001498CrossRef
Zurück zum Zitat Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Can Res 69:2912–2918. https://doi.org/10.1158/0008-5472.CAN-08-3667 CrossRef Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, Oommen NB, Hawche G, Jameson C, Thompson E, Sipkema R, Carden CP, Parker C, Dearnaley D, Kaye SB, Cooper CS, Molina A, Cox ME, Terstappen LW, de Bono JS (2009) Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Can Res 69:2912–2918. https://​doi.​org/​10.​1158/​0008-5472.​CAN-08-3667 CrossRef
Zurück zum Zitat Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG (2013) TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 19:5202–5209. https://doi.org/10.1158/1078-0432.CCR-13-1049 CrossRef Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG (2013) TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res 19:5202–5209. https://​doi.​org/​10.​1158/​1078-0432.​CCR-13-1049 CrossRef
Zurück zum Zitat Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009) TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 8:125–130CrossRef Darnel AD, Lafargue CJ, Vollmer RT, Corcos J, Bismar TA (2009) TMPRSS2-ERG fusion is frequently observed in Gleason pattern 3 prostate cancer in a Canadian cohort. Cancer Biol Ther 8:125–130CrossRef
Zurück zum Zitat Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599. https://doi.org/10.1038/sj.onc.1210237 CrossRefPubMed Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, Hoshida Y, Mosquera JM, Pawitan Y, Lee C, Adami HO, Mucci LA, Kantoff PW, Andersson SO, Chinnaiyan AM, Johansson JE, Rubin MA (2007) TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 26:4596–4599. https://​doi.​org/​10.​1038/​sj.​onc.​1210237 CrossRefPubMed
Zurück zum Zitat Dong J, Xiao L, Sheng L, Xu J, Sun ZQ (2014) TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac J Cancer Prev 15:3099–3103CrossRef Dong J, Xiao L, Sheng L, Xu J, Sun ZQ (2014) TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China. Asian Pac J Cancer Prev 15:3099–3103CrossRef
Zurück zum Zitat Facher EA, Law JC (1998) PTEN and prostate cancer. J Med Genet 35:790CrossRef Facher EA, Law JC (1998) PTEN and prostate cancer. J Med Genet 35:790CrossRef
Zurück zum Zitat Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243. https://doi.org/10.1038/nature11125 CrossRefPubMedPubMedCentral Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487:239–243. https://​doi.​org/​10.​1038/​nature11125 CrossRefPubMedPubMedCentral
Zurück zum Zitat Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB (2009) Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 22:1176–1185CrossRef Han B, Mehra R, Suleman K, Tomlins SA, Wang L, Singhal N, Linetzky KA, Palanisamy N, Zhou M, Chinnaiyan AM, Shah RB (2009) Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod Pathol 22:1176–1185CrossRef
Zurück zum Zitat Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, Li W (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96:3560–3568CrossRef Hyun T, Yam A, Pece S, Xie X, Zhang J, Miki T, Gutkind JS, Li W (2000) Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood 96:3560–3568CrossRef
Zurück zum Zitat Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J, Squire JA, Bismar TA (2011) Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 11:562–566CrossRef Liu S, Yoshimoto M, Trpkov K, Duan Q, Firszt M, Corcos J, Squire JA, Bismar TA (2011) Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone. Cancer Biol Ther 11:562–566CrossRef
Zurück zum Zitat Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Can Res 66:8337–8341CrossRef Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG, Kuefer R, Vessella R, Sun XW, Meyerson M, Lee C, Sellers WR, Chinnaiyan AM, Rubin MA (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Can Res 66:8337–8341CrossRef
Zurück zum Zitat Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882–888CrossRef Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM, Rubin MA (2007) TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 31:882–888CrossRef
Zurück zum Zitat Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678–684. https://doi.org/10.1038/sj.bjc.6605554 CrossRefPubMedPubMedCentral Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM, Foster CS, Fletcher A, Gerald WL, Moller H, Reuter VE, Scardino PT, Cuzick J, de Bono JS, Cooper CS (2010) Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 102:678–684. https://​doi.​org/​10.​1038/​sj.​bjc.​6605554 CrossRefPubMedPubMedCentral
Zurück zum Zitat Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648CrossRef Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310:644–648CrossRef
Zurück zum Zitat Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13:519–528CrossRef Tomlins SA, Rhodes DR, Yu J, Varambally S, Mehra R, Perner S, Demichelis F, Helgeson BE, Laxman B, Morris DS, Cao Q, Cao X, Andren O, Fall K, Johnson L, Wei JT, Shah RB, Al-Ahmadie H, Eastham JA, Eggener SE, Fine SW, Hotakainen K, Stenman UH, Tsodikov A, Gerald WL, Lilja H, Reuter VE, Kantoff PW, Scardino PT, Rubin MA, Bjartell AS, Chinnaiyan AM (2008) The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 13:519–528CrossRef
Zurück zum Zitat Vinceneux A, Bruyere F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Roupret M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G (2017) Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate 77:1242–1250. https://doi.org/10.1002/pros.23383 CrossRefPubMed Vinceneux A, Bruyere F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Roupret M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G (2017) Ductal adenocarcinoma of the prostate: clinical and biological profiles. Prostate 77:1242–1250. https://​doi.​org/​10.​1002/​pros.​23383 CrossRefPubMed
Metadaten
Titel
Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication
verfasst von
Ramy A. Abdelsalam
Ibrahim Khalifeh
Alan Box
Maria Kalantarian
Sunita Ghosh
Hatem Abou-Ouf
Tamara Lotfi
Mohammed Shahait
Nallasivam Palanisamy
Tarek A. Bismar
Publikationsdatum
30.04.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 7/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03221-x

Weitere Artikel der Ausgabe 7/2020

Journal of Cancer Research and Clinical Oncology 7/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.